Palisade Bio, Inc. (PALI)
PALI moved a median of -0.61% 30 minutes after news, and -0.59% by the close. How PALI actually reacts to news — the realized, point-in-time move the market made, measured across 309 labeled events over the last three years with zero look-ahead.
PALI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 300 |
| 30-min | -0.61% | 42% | 307 |
| 60-min | -0.55% | 40% | 309 |
| to close | -0.59% | 43% | 306 |
| Middle 50% of PALI reactions | -2.94% to +0.91% |
|---|---|
| Median reaction (30-min) | -0.61% |
| Measured reactions | 309 |
Half of all Palisade Bio, Inc. news events land between -2.94% and +0.91% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PALI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.93% | 73% | +6.38% |
| Coverage initiations | 23 | +2.75% | 70% | -0.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how PALI ranks against every other measured name →
That’s how PALI usually reacts — get an email when it moves on news →Email me when PALI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PALI's baseline. Nothing else.
Recent PALI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 | Press release | GlobeNewswire | -0.65% | +3.92% | |
| Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 | Press release | GlobeNewswire | +0.34% | +3.45% | |
| Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance | Press release | GlobeNewswire | -1.18% | -5.33% | |
| Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD | Press release | GlobeNewswire | -0.58% | -1.17% | |
| Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum | Press release | GlobeNewswire | -1.52% | +3.05% | |
| Palisade Bio to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +1.74% | |
| Palisade Bio to Participate in the Leerink Partners Therapeutics Forum | Press release | GlobeNewswire | -2.51% | -1.51% | |
| Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | Press release | GlobeNewswire | +6.75% | +16.75% | |
| Form 8-K PALISADE BIO, INC. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -3.93% | |
| Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors | Press release | GlobeNewswire | -0.30% | +6.59% | |
| Form S-8 PALISADE BIO, INC. | SEC filing · Form S-8 | SEC EDGAR | -0.30% | +6.59% | |
| Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium | Press release | GlobeNewswire | +0.57% | -3.43% | |
| Palisade Bio to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +3.06% | +5.61% | |
| Form EFFECT PALISADE BIO, INC. | SEC filing · Form EFFECT | SEC EDGAR | +1.29% | -2.98% | |
| Form 10-Q PALISADE BIO, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.04% | -2.60% | |
| Form 8-K PALISADE BIO, INC. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | -2.60% | |
| Form S-3 PALISADE BIO, INC. | SEC filing · Form S-3 | SEC EDGAR | +1.04% | -2.60% | |
| Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 | Press release | GlobeNewswire | +1.04% | -2.60% | |
| Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis | Press release | GlobeNewswire | +2.08% | -8.80% | |
| Form ARS PALISADE BIO, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.26% | +2.56% | |
| Form DEF 14A PALISADE BIO, INC. For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | -0.26% | +2.56% | |
| Form DEFA14A PALISADE BIO, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.26% | +2.56% | |
| Form PRE 14A PALISADE BIO, INC. For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | +2.35% | +6.84% | |
| Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 | Press release | GlobeNewswire | +0.00% | +1.75% | |
| Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference | Press release | GlobeNewswire | +1.02% | -4.59% | |
| Form 8-K PALISADE BIO, INC. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | +2.16% | |
| Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease | Press release | GlobeNewswire | +3.98% | -0.57% | |
| Form 10-K PALISADE BIO, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.26% | +0.00% | |
| Palisade Bio Announces Participation in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +1.14% | +3.43% | |
| Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 | Press release | GlobeNewswire | +0.94% | +0.63% | |
| Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board | Press release | GlobeNewswire | -2.92% | -0.58% | |
| Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium | Press release | GlobeNewswire | +0.00% | +6.83% | |
| Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -0.64% | -3.85% | |
| Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board | Press release | GlobeNewswire | -4.73% | -4.73% | |
| Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences | Press release | GlobeNewswire | -0.84% | -7.26% | |
| Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108 | Press release | GlobeNewswire | +2.02% | +2.02% | |
| Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 | Press release | GlobeNewswire | -6.49% | -10.61% | |
| Form 8-K PALISADE BIO, INC. For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | -2.76% | -0.55% | |
| Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development | Press release | GlobeNewswire | -1.59% | -2.66% | |
| Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.22% | -5.70% | |
| Form S-8 PALISADE BIO, INC. | SEC filing · Form S-8 | SEC EDGAR | -0.25% | — | |
| Form 10-Q PALISADE BIO, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.85% | +3.41% | |
| Form DEFA14A PALISADE BIO, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +3.16% | -3.67% | |
| Form DEF 14A PALISADE BIO, INC. For: Oct 28 | SEC filing · Form DEF | SEC EDGAR | -0.78% | +9.85% | |
| Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations | Press release | GlobeNewswire | +0.00% | +10.78% | |
| Form 8-K PALISADE BIO, INC. For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | +3.11% | +10.63% | |
| Form 8-K PALISADE BIO, INC. For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -4.32% | |
| Form PRE 14A PALISADE BIO, INC. For: Oct 17 | SEC filing · Form PRE | SEC EDGAR | +3.47% | +7.51% | |
| Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD) | Press release | GlobeNewswire | +3.47% | +7.51% | |
| Form 8-K PALISADE BIO, INC. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +3.51% | +1.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PALI section they belong to.
Where else PALI is measured.
PALI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Palisade Bio, Inc.'s median reaction calculated?
Every labeled PALI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 309 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of PALI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PALI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.